Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS:
After treatment, the 67Ga scan remained positive in four patients and was interpreted as negative in 97. Among the four patients with positive scans, two died of progressive disease and two relapsed. Among the remaining 97 patients with negative 67Ga scans, 16 patients relapsed, including five with stage I to II (7.5%) and 11 with stage III to IV (34.4%) disease. The negative predictive value of posttherapy 67Ga scan was 83.5% for all patients; however, when calculated according to stage, it was 92.4% for patients with stage I to II disease and 64.5% for patients with stage III to IV disease (P < .01). CONCLUSION: A positive 67Ga scan at the end of therapy is rarely seen in patients with Hodgkin's disease and should be considered a manifestation of gross residual disease. However, a negative 67Ga scan after therapy had a significantly lower predictive value in patients with stage III to IV disease compared with stage I to II disease. The predictive value of 67Ga scans, as well as newer imaging studies, should be analyzed according to pretreatment stage.
|
Authors | E Salloum, D S Brandt, V J Caride, E Cornelius, D Zelterman, W Schubert, T Mannino, D L Cooper |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 15
Issue 2
Pg. 518-27
(Feb 1997)
ISSN: 0732-183X [Print] United States |
PMID | 9053473
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemotherapy, Adjuvant
- Child
- Female
- Gallium Radioisotopes
- Hodgkin Disease
(diagnostic imaging, pathology, therapy)
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Predictive Value of Tests
- Radiotherapy, Adjuvant
- Tomography, Emission-Computed, Single-Photon
- Treatment Outcome
|